低分子肝素治疗急性肺栓塞的疗效

Efficacy of Low Molecular Weight Heparin in the Treatment of Acute Pulmonary Embolism

目的探讨急性肺栓塞患者采用低分子肝素治疗的效果,为临床治疗该病提供参考。方法选取2017年1月~2018年12月我院收治的急性肺栓塞患者78例,采用随机数字表法分为对照组和研究组,每组39例。对照组进行普通肝素治疗,研究组行低分子肝素治疗。比较两组临床疗效、二氧化碳分压(PaCO2)、血氧分压(PaO2)、心率、肺动脉压力、MRC呼吸困难评分。结果研究组治疗总有效率为92.31%,高于对照组的79.48%,差异有统计学意义(P<0.05);研究组的PaCO2水平为(36.94±3.04)mmHg、PaO2水平为(87.29±3.36)mmHg,高于对照组的(30.37±3.63)mmHg、(76.48±3.37)mmHg,差异有统计学意义(P<0.05);研究组心率为(68.55±10.12)次/min,低于对照组的(78.57±10.29)次/min,差异有统计学意义(P<0.05);研究组的肺动脉压力为(20.05±6.23)mmHg、MRC呼吸困难评分为(1.22±0.97)分,低于对照组的(26.64±7.99)mmHg、(2.44±0.84)分,差异有统计学意义(P<0.05)。结论采用低分子肝素治疗急性肺栓塞可提升临床治疗效果,改善患者二氧化碳分压、血氧分压、心率及肺动脉压力水平,降低MRC呼吸困难评分。

Objective To explore the effect of low-molecular-weight heparin in patients with acute pulmonary embolism,and provide references for clinical treatment of the disease.Methods A total of 78 patients with acute pulmonary embolism admitted to our hospital from January 2017 to December 2018 were selected and divided into control group and study group by random number table,with 39 cases in each group.The control group received unfractionated heparin treatment,and the study group received low molecular weight heparin treatment.The clinical efficacy,partial pressure of carbon dioxide(PaCO2),partial pressure of blood oxygen(PaO2),heart rate,pulmonary artery pressure,and MRC dyspnea score were compared between the two groups.Results The total effective rate of treatment in the study group was 92.31%,which was higher than 79.48% in the control group,the difference was statistically significant(P<0.05);the PaCO2 level of the study group was(36.94±3.04)mmHg and the PaO2 level was(87.29±3.36)mmHg,higher than the control group(30.37±3.63)mmHg,(76.48±3.37)mmHg,the difference was statistically significant(P<0.05);the study group's heart rate was(68.55±10.12)beats/min,lower than the control group(78.57±10.29)times/min,the difference was statistically significant(P<0.05);the pulmonary artery pressure of the study group was(20.05±6.23)mmHg,and the MRC dyspnea score was(1.22±0.97),which was lower than that of the control group(26.64±7.99)mmHg,(2.44±0.84),the difference was statistically significant(P<0.05).Conclusion The use of low molecular weight heparin in the treatment of acute pulmonary embolism could improve the clinical treatment effect,improve the patients'carbon dioxide partial pressure,blood oxygen partial pressure,heart rate and pulmonary artery pressure levels,and reduce the MRC dyspnea score.